We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Clorox Divests Aplicare Skin Unit to Medline Industries
Read MoreHide Full Article
The Clorox Company (CLX - Free Report) announced the sale of its Aplicare skin antisepsis business to Medline Industries. This was done in accordance with the former’s 2020 Strategy, which is aimed at boosting growth for the improvement of categories and overall market share. However, the financial terms of the deal that concluded on Aug 21, remained under covers.
Notably, Aplicare business that was part of Clorox’s Professional Products business, contributed nearly $46 million in fiscal 2017, reflecting not more than 1% of the company’s overall sales as well as insignificant earnings.
In fact, the Illinois-based Medline Industries, which is the leading privately-held maker and distributor of medical supplies, is likely to enhance the performance of the Aplicare business with its solid capabilities and explorations. Also, it will cater top-tier health care products and services to its customers.
With the sale of its Aplicare skin unit, Clorox does not free itself from the responsibility of focusing strategically on its Professional Products business and the company will continue to stop the spread of infection as well as kill pathogens.
Throwing light upon Clorox’s 2020 Strategy, we note that the strategy is aimed at achieving certain long-term aspirations, including growing net sales by 3-5%, increasing EBIT margin by 25-50 basis points and generating free cash flow of 10-12% of sales, all on a yearly basis.
Meanwhile, Clorox seems to be well on track with the execution of the strategy, which is meant to be achieved through key accelerators like investment in brands; development of eCommerce; technological advancements; enhancement of growth culture and focus on the 3Ds – desire, decision and delight.
Evidently, the 2020 Strategy coupled with other factors drove the company’s fiscal 2017 performance. Going forward, Clorox is likely to deliver another year of solid earnings and sales growth in fiscal 2018 aided by these factors. Concurrently, management has also stated that it will issue an updated outlook for fiscal 2018 on Nov 1, when it reports fiscal first-quarter results.
In fact, shares of Clorox have outpaced the broader Consumer Staples sector in the last three months. This Zacks Rank #3 (Hold) stock rallied 4.7%, as against the sector’s fall of 0.3%. Currently, the sector is placed at the top 25% of the Zacks classified sectors (4 out of 16).
Finding Consumer Staples Space Interesting? Check These Out
Better-ranked stocks in the broader sector include Unilever N.V. , Ollie's Bargain Outlet Holdings, Inc. (OLLI - Free Report) and Ingredion Incorporated (INGR - Free Report) .
Ollie's Bargain, with a long-term earnings growth rate of 19% has pulled off an average positive earnings surprise of 14.6% in the last four quarters. It carries a Zacks Rank #2 (Buy).
Ingredion, a Zacks Rank #2 stock has delivered an average positive earnings surprise of 4.9% in the trailing four quarters.
4 Surprising Tech Stocks to Keep an Eye on
Tech stocks have been a major force behind the market’s record highs, but picking the best ones to buy can be tough. There’s a simple way to invest in the success of the entire sector. Zacks has just released a Special Report revealing one thing tech companies literally cannot function without. More importantly, it reveals 4 top stocks set to skyrocket on increasing demand for these devices. I encourage you to get the report now – before the next wave of innovations really takes off.
Image: Bigstock
Clorox Divests Aplicare Skin Unit to Medline Industries
The Clorox Company (CLX - Free Report) announced the sale of its Aplicare skin antisepsis business to Medline Industries. This was done in accordance with the former’s 2020 Strategy, which is aimed at boosting growth for the improvement of categories and overall market share. However, the financial terms of the deal that concluded on Aug 21, remained under covers.
Notably, Aplicare business that was part of Clorox’s Professional Products business, contributed nearly $46 million in fiscal 2017, reflecting not more than 1% of the company’s overall sales as well as insignificant earnings.
In fact, the Illinois-based Medline Industries, which is the leading privately-held maker and distributor of medical supplies, is likely to enhance the performance of the Aplicare business with its solid capabilities and explorations. Also, it will cater top-tier health care products and services to its customers.
With the sale of its Aplicare skin unit, Clorox does not free itself from the responsibility of focusing strategically on its Professional Products business and the company will continue to stop the spread of infection as well as kill pathogens.
Throwing light upon Clorox’s 2020 Strategy, we note that the strategy is aimed at achieving certain long-term aspirations, including growing net sales by 3-5%, increasing EBIT margin by 25-50 basis points and generating free cash flow of 10-12% of sales, all on a yearly basis.
Meanwhile, Clorox seems to be well on track with the execution of the strategy, which is meant to be achieved through key accelerators like investment in brands; development of eCommerce; technological advancements; enhancement of growth culture and focus on the 3Ds – desire, decision and delight.
Evidently, the 2020 Strategy coupled with other factors drove the company’s fiscal 2017 performance. Going forward, Clorox is likely to deliver another year of solid earnings and sales growth in fiscal 2018 aided by these factors. Concurrently, management has also stated that it will issue an updated outlook for fiscal 2018 on Nov 1, when it reports fiscal first-quarter results.
In fact, shares of Clorox have outpaced the broader Consumer Staples sector in the last three months. This Zacks Rank #3 (Hold) stock rallied 4.7%, as against the sector’s fall of 0.3%. Currently, the sector is placed at the top 25% of the Zacks classified sectors (4 out of 16).
Finding Consumer Staples Space Interesting? Check These Out
Better-ranked stocks in the broader sector include Unilever N.V. , Ollie's Bargain Outlet Holdings, Inc. (OLLI - Free Report) and Ingredion Incorporated (INGR - Free Report) .
Unilever has gained 28.3% in the last one year and currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Ollie's Bargain, with a long-term earnings growth rate of 19% has pulled off an average positive earnings surprise of 14.6% in the last four quarters. It carries a Zacks Rank #2 (Buy).
Ingredion, a Zacks Rank #2 stock has delivered an average positive earnings surprise of 4.9% in the trailing four quarters.
4 Surprising Tech Stocks to Keep an Eye on
Tech stocks have been a major force behind the market’s record highs, but picking the best ones to buy can be tough. There’s a simple way to invest in the success of the entire sector. Zacks has just released a Special Report revealing one thing tech companies literally cannot function without. More importantly, it reveals 4 top stocks set to skyrocket on increasing demand for these devices. I encourage you to get the report now – before the next wave of innovations really takes off.
See Stocks Now>>